UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of Earliest Event Reported): December 18, 2020

 


 

Cleveland BioLabs, Inc.

(Exact Name of Registrant as Specified in Charter)

 


 

DELAWARE

001-32954

20-0077155

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

     

73 High Street

Buffalo, NY 14203

(Address of Principal Executive Offices and zip code)

 

 

 

 

(716) 849-6810

 

(Registrant's Telephone Number, Including Area Code)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.005

CBLI

NASDAQ Capital Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                                                

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 



 

 

 

Item 5.07         Submission of Matters to a Vote of Security Holders.

 

Cleveland BioLabs, Inc. (the “Company”) held its Annual Meeting of Stockholders virtually on December 18, 2020 (the “2020 Annual Meeting”). The results of matters submitted to a stockholder vote at the 2020 Annual Meeting are as follows:

 

Proposal No. 1: Election of Directors. Six nominees were elected to serve on the Company’s board of directors until the next annual meeting of stockholders and until their successors are elected and qualified with the votes set forth below:

 

Nominee

For

Withheld

Broker Non-Votes

Alexander Andryushechkin

7,518,016

112,073

3,665,783

Anna Evdokimova

7,532,184

97,905

3,665,783

Ivan Fedyunin

7,533,073

97,016

3,665,783

Randy S. Saluck

7,518,725

111,364

3,665,783

Daniil Talyanskiy

7,531,041

99,048

3,665,783

Lea Verny

7,519,275

110,814

3,665,783

 

 

Proposal No. 2: Ratification of Meaden & Moore, Ltd. as the independent registered public accounting firm for fiscal year ending December 31, 2020. The selection of Meaden & Moore, Ltd. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020 was ratified with the votes set forth below:

 

For

Against

Abstain

10,482,363

22,461

791,048

 

Proposal No. 3: Approval by an advisory vote the compensation of the Companys named executive officers. The compensation of the Company’s named executive officers was approved in an advisory vote with the votes set forth below:

 

For

Against

Abstain

Broker Non-Vote

7,294,410

302,237

33,442

3,665,783

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Cleveland BioLabs, Inc.
   
Date: December 21, 2020 By: /s/ Christopher Zosh
  Name: Christopher Zosh
  Title: Vice President of Finance